Efectividad y análisis farmacoeconómico del tratamiento del asma grave con omalizumab en la práctica clínica

Martínez-Moragón, Eva; Climent, María; Chiner, Eusebi; Fernández-Aracil, Cleofé; Sánchez-Toril, Fernando; Lluch-Tortajada, Inmaculada.
Farm. hosp ; 43(3): 101-109, mayo-jun. 2019. tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-183012

Documentos relacionados

  1. Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice.
  2. The economic burden of severe asthma in children: a comprehensive study.
  3. Trends in the Cost and Utilization of Omalizumab in the Medicare Population: 2013-2017.
  4. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland.
  5. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
  6. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
  7. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab.
  8. Impact of omalizumab on medical cost of childhood asthma in Japan.
  9. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.
  10. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States.